Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 809-823

  Menéndez Gutiérrez, María P ^a   Rõszer, Tamás ^a,b   Fuentes, Lucía ^a   Núnez, Vanessa ^a   Escolano, Amelia ^a   Redondo, Juan Miguel ^a   De Clerck, Nora ^c   Metzger, Daniel ^d   Valledor, Annabel F ^e   Ricote, Mercedes ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER X RECEPTOR; RETINOID X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR MAFB; MAFB PROTEIN, MOUSE; ORPHAN NUCLEAR RECEPTOR; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ARTICLE; BONE MASS; BONE REMODELING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STEM CELL; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; OSTEOPOROSIS; PHYSIOLOGY; PROTEIN MULTIMERIZATION; UPREGULATION;

ANIMALS; BONE REMODELING; CELL DIFFERENTIATION; FEMALE; MAFB TRANSCRIPTION FACTOR; MALE; MICE; MICE, KNOCKOUT; ORPHAN NUCLEAR RECEPTORS; OSTEOCLASTS; OSTEOPOROSIS; PROTEIN MULTIMERIZATION; RETINOID X RECEPTORS; STEM CELLS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84922169574     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77186     Document Type: Article

References (68)

1. Kanis JA, McCloskey EV, Johansson H, Oden A. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009;5(8):425-431.
2. Di Girolamo DJ, Clemens TL, Kousteni S. The skeleton as an endocrine organ. Nat Rev Rheumatol. 2012;8(11):674-683.
3. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013;54(2):258-263.
4. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6(2):99-105.
5. Vanderschueren D, Boonen S, Bouillon R. Physiology of calcium homeostasis and bone remodeling. In: Geusens P, Sambrook P, Lindsay R, eds. Osteoporosis in Clinical Practice: A Practical Guide for Diagnosis and Treatment. 2nd ed. London, United Kingdom: Springer London; 2004:9-14.
6. Harre U, Schett G. Bone research in 2012: The ups and downs of bone in health and rheumatic disease. Nat Rev Rheumatol. 2013;9(2):67-68.
7. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276-1287.
8. Rõszer T, Menéndez-Gutiérrez MP, Cedenilla M, Ricote M. Retinoid X receptors in macrophage biology. Trends Endocrinol Metab. 2013;24(9):460-468.
9. Miyazaki S, et al. Nuclear hormone retinoid X receptor (RXR) negatively regulates the glucosestimulated insulin secretion of pancreatic sscells. Diabetes. 2010;59(11):2854-2861.
10. Hamann C, Kirschner S, Gunther KP, Hofbauer LC. Bone, sweet bone - osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8(5):297-305.
11. Ricote M, Snyder CS, Leung HY, Chen J, Chien KR, Glass CK. Normal hematopoiesis after conditional targeting of RXRalpha in murine hematopoietic stem/progenitor cells. J Leukoc Biol. 2006;80(4):850-861.
12. Kastner P, et al. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev. 1996;10(1):80-92.
13. Lotinun S, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666-681.
14. Tran Van P, Vignery A, Baron R. An electronmicroscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res. 1982;225(2):283-292.
15. Lomaga MA, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999;13(8):1015-1024.
16. Kikuta J, Ishii M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology. 2013;52(2):226-234.
17. Bozec A, et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature. 2008;454(7201):221-225.
18. Lees RL, Heersche JN. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. J Bone Miner Res. 1999;14(6):937-945.
19. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-649.
20. Insogna KL, et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-srcdependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest. 1997;100(10):2476-2485.
21. Calle Y, et al. WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption. Blood. 2004;103(9):3552-3561.
22. Chiusaroli R, et al. Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. Mol Biol Cell. 2004;15(1):234-244.
23. Jurdic P, Saltel F, Chabadel A, Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol. 2006;85(3):195-202.
24. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
25. De Vries TJ, Schoenmaker T, Hooibrink B, Leenen PJ, Everts V. Myeloid blasts are the mouse bone marrow cells prone to differentiate into osteoclasts. J Leukoc Biol. 2009;85(6):919-927.
26. Sarrazin S, et al. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell. 2009;138(2):300-313.
27. Aziz A, Soucie E, Sarrazin S, Sieweke MH. MafB/c-Maf deficiency enables self-renewal of differentiated functional macrophages. Science. 2009;326(5954):867-871.
28. Lala DS, et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996;383(6599):450-453.
29. Nunez V, et al. Retinoid X receptor alpha controls innate inflammatory responses through the upregulation of chemokine expression. Proc Natl Acad Sci U S A. 2010;107(23):10626-10631.
30. Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 2010;21(11):676-683.
31. Kim K, et al. MafB negatively regulates RANKLmediated osteoclast differentiation. Blood. 2007;109(8):3253-3259.
32. Teti A. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep. 2013;2:449.
33. Fujita K, et al. Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 2012;18(4):589-594.
34. Jilka RL. The relevance of mouse models for investigating age-related bone loss in humans. J Gerontol A Biol Sci Med Sci. 2013;68(10):1209-1217.
35. Cao J, Venton L, Sakata T, Halloran BP. Expression of RANKL and OPG correlates with agerelated bone loss in male C57BL/6 mice. J Bone Miner Res. 2003;18(2):270-277.
36. Liu CC, Howard GA. Bone-cell changes in estrogen-induced bone-mass increase in mice: dissociation of osteoclasts from bone surfaces. Anat Rec. 1991;229(2):240-250.
37. Takano-Yamamoto T, Rodan GA. Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci U S A. 1990;87(6):2172-2176.
38. Song MR, Lee SK, Seo YW, Choi HS, Lee JW, Lee MO. Differential modulation of transcriptional activity of oestrogen receptors by direct proteinprotein interactions with retinoid receptors. Biochem J. 1998;336(pt 3):711-717.
39. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci. 2009;66(15):2405-2426.
40. Wan Y, Chong LW, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat Med. 2007;13(12):1496-1503.
41. Bland R. Steroid hormone receptor expression and action in bone. Clin Sci (Lond). 2000;98(2):217-240.
42. Robertson KM, et al. Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. J Bone Miner Res. 2006;21(8):1276-1287.
43. Remen KM, Henning P, Lerner UH, Gustafsson JA, Andersson G. Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism. J Biol Chem. 2011;286(38):33084-33094.
44. Scholtysek C, et al. PPARbeta/delta governs Wnt signaling and bone turnover. Nat Med. 2013;19(5):608-613.
45. Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim Biophys Acta. 2012;1821(1):21-56.
46. Rahman MM, Bhattacharya A, Banu J, Kang JX, Fernandes G. Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis. J Cell Mol Med. 2009;13(8):1833-1844.
47. Kelly OJ, Gilman JC, Kim Y, Ilich JZ. Long-chain polyunsaturated fatty acids may mutually benefit both obesity and osteoporosis. Nutr Res. 2013;33(7):521-533.
48. Conaway HH, et al. Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. FASEB J. 2009;23(10):3526-3538.
49. Hu L, Lind T, Sundqvist A, Jacobson A, Melhus H. Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK. PLoS One. 2010;5(10):e13305.
50. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86(11):839-848.
51. Cornish J, et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology. 2008;149(11):5688-5695.
52. Bab I, Smoum R, Bradshaw H, Mechoulam R. Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol. 2011;163(7):1441-1446.
53. Grasser WA, et al. Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact. 2003;3(1):53-62.
54. Mukherjee R, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997;386(6623):407-410.
55. Li M, Messaddeq N, Teletin M, Pasquali JL, Metzger D, Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A. 2005;102(41):14795-14800.
56. Peet DJ, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRa. Cell. 1998;93(5):693-704.
57. Pascual-Garcia M, et al. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. J Immunol. 2011;186(8):4656-4667.
58. Akiyama TE, et al. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22(8):2607-2619.
59. Fuchs H, Lisse T, Abe K, De Angelis MH. Screening for bone and cartilage phenotypes in mice. In: De Angelis MH, Chambon P, Brown S, eds. Standards of Mouse Model Phenotyping. Datenschutz, Germany: Wiley-VCH Verlag GmbH; 2008:35-86.
60. Sontag W. Quantitative measurement of periosteal and cortical-endosteal bone formation and resorption in the midshaft of female rat femur. Bone. 1986;7(1):55-62.
61. Roszer T, et al. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor α deficiency. J Immunol. 2011;186(1):621-631.
62. Nikolic T, De Bruijn MF, Lutz MB, Leenen PJ. Developmental stages of myeloid dendritic cells in mouse bone marrow. Int Immunol. 2003;15(4):515-524.
63. Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J. 2000;350(pt 2):389-393.
64. Ovcharenko I, et al. Mulan: multiple-sequence local alignment and visualization for studying function and evolution. Genome Res. 2005;15(1):184-194.
65. Heinz S, et al. Simple combinations of lineagedetermining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576-589.
66. Ricote M, et al. Expression of the peroxisome proliferatoractivated receptor g (PPARg) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95(13):7614-7619.
67. Lefterova MI, et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol Cell Biol. 2010;30(9):2078-2089.
68. Fuller K, Kirstein B, Chambers TJ. Murine osteoclast formation and function: differential regulation by humoral agents. Endocrinology. 2006;147(4):1979-1985.